What is INSM stock forecast?

Insmed Inc forecast includes bull, base, and bear case scenarios from 2026 through 2030. Revenue and EPS projections are derived from analyst consensus and conservative extrapolation with growth deceleration for outer years.

INSM

Insmed Inc

NASDAQ: INSM · HEALTHCARE · BIOTECHNOLOGY

$136.33

+0.96% today

Updated 2026-04-30

Market cap

$29.15B

P/E ratio

—

P/S ratio

48.06x

EPS (TTM)

$-6.42

Dividend yield

—

52W range

$64 – $213

Volume

2.3M

Market cap

$29.15B

P/E ratio

—

P/S ratio

48.06x

EPS (TTM)

$-6.42

Dividend yield

—

52W range

$64 – $213

Volume

2.3M

Insmed Inc (INSM) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current

$136.33

Consensus

$200.48

+47.05%

2030 Target

$389.83

+185.95%

DCF

—

Current price

$136.33

Analyst consensus

$200.48

+47.05%

2030 Target

$389.83

+185.95%

Intrinsic (DCF)

—

24 analysts:

10 Buy1 Hold0 Sell

Management guidance

CEO William Lewis has not disclosed specific revenue targets for 2026-2030 in the available documents. However, management guided to strong 2026 commercial execution with ARIKAYCE (amikacin liposome inhalation suspension) and Brinsupri (treprostinil palmitil inhalation powder) as primary growth drivers. The company is targeting label expansion for ARIKAYCE based on positive Phase 3b ENCORE data, which management indicated could significantly increase addressable market.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range

Bull case (2030)

$665.96

$7.1B Rev × 20x P/S

Base case (2030)

$389.83

$7.1B Rev × 12x P/S

Bear case (2030)

$259.89

$7.1B Rev × 8x P/S

Financial forecast — research-backed

Metric	2023	2024	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)	2030 (E)
Revenue	$0.3B	$0.4B	$0.6B	$1.7B	$2.8B	$4.2B	$5.6B	$7.1B
Revenue growth	—	19.2%	66.7%	177.0%	66.5%	50.0%	33.3%	26.8%
EPS	$-5.34	$-5.59	$-6.41	$-2.93	$0.48	$2.85	$5.20	$7.80
P/S ratio	—	—	—	12.0x	12.0x	12.0x	12.0x	12.0x
Implied price	—	—	—	$97.46	$162.43	$227.40	$308.62	$389.83

Catalysts & risks

Growth catalysts

+ ARIKAYCE label expansion approval for newly-diagnosed MAC lung disease (Phase 3b ENCORE trial positive results March 2026)

+ Brinsupri commercial launch and ramp in U.S. market (newly approved lung disease drug gaining market traction)

+ TPIP (treprostinil palmitil inhalation powder) Phase 3 initiation for IPF expected H2 2026

+ INS1202 gene therapy Phase 1 for ALS launched March 2026 (new pipeline expansion)

Key risks

- Insider selling by CEO and COO (William Lewis and Roger Adsett sold shares March-April 2026) signals potential valuation concerns

- Deeply negative profit margins (-210.5%) despite high revenue growth indicate significant R&D and commercial expenses not yet controlled

- Patent cliff risks on core products ARIKAYCE and Brinsupri could impact revenue trajectory post-2028

- Competition in pulmonary/rare disease space; regulatory approval timing uncertainty for label expansions

Methodology

Insmed Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 24 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.